Gland Pharma appoints Wei Huang as Additional Director in category of Non-Executive, Non Independent Director
Telangana: Gland Pharma has announced the appointment of Wei Huang as an Additional Director in the category of Non-Executive & Non-Independent Director of the Company, liable to retire by rotation, with effect from November 04, 2024.
Wei Huang is currently the President of Shanghai Henlius Biotech Inc., responsible for the production and supply of the Company's clinical and commercial products, design and implementation of engineering projects, continuous improvement and optimization of production capacity. She is also the Chairman of Aton (Shanghai) Biotech Co., Ltd.
Wei Huang has leadership experience in pharmaceutical and biotechnology industry spanning over 30 years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation. She joined Fosun Pharma Group and served as Senior Vice President, Chief Operating Officer, and President of Shanghai Henlius Biotech Inc. since Dec. 2019.
Prior to that, Huang served as Chief Adviser of NEWA Technology Inc., responsible for areas such as project management, manufacturing, validation, process development and CMC, cGMP compliance audits, techno-economic assessment, gap and risk mitigation, and strategic guidance for the company. Prior to NEWA, Ms. Huang, during 2008-2013 served as Vice President of Process Development and Engineering of REG Life Sciences Corporation.
Huang holds Master’s degree from University of Maryland in Chemical and Biochemical Engineering and Bachelor’s degree from East China University of Science and Technology in Biochemical Engineering.
Read also: Gland Pharma names Shyamakant Giri as new CEO
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and markets sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
